Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Behrens

Showing results (41-50 of 119) with videos related to

Pageof 12
Sort By:
Scientific Reports|December 20, 2023
Machine learning identifies right index finger tenderness as key signal of DAS28-CRP based psoriatic arthritis activitySamuel Rischke, Sorwe Mojtahed Poor, Robert Gurke, et al.
Rheumatology (Oxford, England)|April 25, 2023
Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED studyGurjit S Kaeley, Georg Schett, Philip G Conaghan, et al.
The Journal of Rheumatology|December 17, 2015
Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational StudyFrank Behrens, Michaela Koehm, Uta Arndt, et al.
Rheumatology and Therapy|December 30, 2022
PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic ArthritisStefan Siebert, Frank Behrens, Ennio Lubrano, et al.
Clinical Rheumatology|May 2, 2022
Sensory testing and topical capsaicin can characterize patients with rheumatoid arthritisBjoern Anders, Malte Anders, Matthias Kreuzer, et al.
Rheumatology International|February 11, 2020
Individual therapeutic DAS28-d<sub>crit</sub> responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studiesMichaela Koehm, Matthew J McIntosh, Michael W Hofmann, et al.
Arthritis and Rheumatism|December 1, 2011
Tumor necrosis factor promoter polymorphism TNF*-857 is a risk allele for psoriatic arthritis independent of the PSORS1 locusEmiliano Giardina, Ulrike Hüffmeier, Jaya Ravindran, et al.
Arthritis and Rheumatism|June 10, 2004
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trialJ Peter Kaltwasser, Peter Nash, Dafna Gladman, et al.
RMD Open|August 31, 2023
Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort studyMichaela Koehm, Maximilian Klippstein, Stephanie Dauth, et al.
Rheumatology and Therapy|February 3, 2022
Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported OutcomesEugen Feist, Xenofon Baraliakos, Frank Behrens, et al.
Pageof 12

Showing results (41-50 of 119) with videos related to

Sort By:
Pageof 12
Scientific Reports|December 20, 2023
Machine learning identifies right index finger tenderness as key signal of DAS28-CRP based psoriatic arthritis activitySamuel Rischke, Sorwe Mojtahed Poor, Robert Gurke, et al.
Rheumatology (Oxford, England)|April 25, 2023
Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED studyGurjit S Kaeley, Georg Schett, Philip G Conaghan, et al.
The Journal of Rheumatology|December 17, 2015
Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational StudyFrank Behrens, Michaela Koehm, Uta Arndt, et al.
Rheumatology and Therapy|December 30, 2022
PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic ArthritisStefan Siebert, Frank Behrens, Ennio Lubrano, et al.
Clinical Rheumatology|May 2, 2022
Sensory testing and topical capsaicin can characterize patients with rheumatoid arthritisBjoern Anders, Malte Anders, Matthias Kreuzer, et al.
Rheumatology International|February 11, 2020
Individual therapeutic DAS28-d<sub>crit</sub> responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studiesMichaela Koehm, Matthew J McIntosh, Michael W Hofmann, et al.
Arthritis and Rheumatism|December 1, 2011
Tumor necrosis factor promoter polymorphism TNF*-857 is a risk allele for psoriatic arthritis independent of the PSORS1 locusEmiliano Giardina, Ulrike Hüffmeier, Jaya Ravindran, et al.
Arthritis and Rheumatism|June 10, 2004
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trialJ Peter Kaltwasser, Peter Nash, Dafna Gladman, et al.
RMD Open|August 31, 2023
Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort studyMichaela Koehm, Maximilian Klippstein, Stephanie Dauth, et al.
Rheumatology and Therapy|February 3, 2022
Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported OutcomesEugen Feist, Xenofon Baraliakos, Frank Behrens, et al.
Pageof 12